Pranoprofen Nanoparticles With Poly(L-Lactide)-b-Poly(Ethylene Glycol)-b-Poly(L-Lactide) as the Matrix Toward Improving Ocular Anti-inflammation

Abstract

Nanotechnology using biodegradable polymer carriers with good biocompatibility and bioabsorbability has been studied and applied extensively in drug delivery systems and biomedical engineering. In this work, the triblocked oligomer poly(L-lactide)-bpoly(ethylene glycol)-b-poly(L-lactide) (PLEL) with the molecular weight of 2.08 KDa was first synthesized. Its chemistry was characterized by hydrogen nuclear magnetic resonance (1 H-NMR) spectrum and Fourier transform infrared (FTIR) spectroscopy. Subsequently, the nanoparticles (NPs) of PLEL and pranoprofen (PF)-loaded PLEL were prepared with the average particle size of (151.7 ± 5.87) nm using the method of emulsion solvent evaporation. The formula and drug releasing profile were characterized by a transmission electron microscope (TEM), dynamic light scattering (DLS), and ultraviolet spectrophotometer (US). In vitro cytotoxicity assays and in vivo ophthalmic tests were performed to measure the safety and efficacy of the formulations. The results showed that PF NPs relieved the cytotoxicity of pure PF and eliminated ophthalmic irritation. The drug encapsulated in the nanoparticles displayed long-lasting release and good anti-inflammation efficiency in animal eyes. Therefore, we concluded that the present formula (PF NPs) could provide sustained drug release with good treatment effect on eye inflammation, and is promising for its use in ophthalmology in the future.

Fabrication and Characterization of Chitosan/Poly(Lactic-Co-glycolic Acid) Core-Shell Nanoparticles by Coaxial Electrospray Technology for Dual Delivery of Natamycin and Clotrimazole

“…By contrast with the administration of the free drugs (NAT and CLZ), the sustained release from the core-shell NPs demonstrates that the developed NPs can be used as an important platform for continuous drug release. This characteristic is expected to prove very useful in providing long-lasting anti-inflammatory effects with low administration frequency ( Luo et al, 2020 ).…”

Evaluating the effect of synthesis, isolation, and characterisation variables on reported particle size and dispersity of drug loaded PLGA nanoparticles

“…3 The degradation products are metabolised via the Krebs cycle and cleared by the body 4 and several studies have reported their biocompatibility in many biological tissues. 1,[4][5][6][7][8] There are many examples in the literature using PLGA-based materials for delivery of therapeutics to promote either fast or prolonged drug release with applications in cancer treatment, pain management, immunotherapy, and more recently, in the treatment of pulmonary tuberculosis, urinary tract infections, migraine and glaucoma. 5,6,[9][10][11][12][13][14][15] There are several techniques that are used for the preparation of PLGA particles including single and double emulsion solvent evaporation (ESE), nanoprecipitation, spray-drying, microfluidics, and hydrogel templating.…”

Mucoadhesive Cationic Bromelain Laden Nanocarriers Restore Patency of Airway Hyperresponsive Remodeling via Nasal Route

“…[25] Thus, results implied that polymeric nanoparticles of Eudragit RL 100 would be having higher structural stability and conserve their integrity upon extreme dilution in biological milieu. [25,38] Polymeric coating over bromelain in Br-EuNCs hindered the penetration of dissolution medium in matrix and promoted prolonged release of drug from polymeric matrix. The results of mucoadhesion study demonstrated that Br-EuNCs had higher mucoadhesive property due to the electrostatic interactions between the positively charged ammonium group of Eudragit RL100 and negatively charged domains of the mucin chains.…”